keyword
MENU ▼
Read by QxMD icon Read
search

Breast endocrine surgery

keyword
https://www.readbyqxmd.com/read/28794284/genomic-profiling-of-er-breast-cancers-after-short-term-estrogen-suppression-reveals-alterations-associated-with-endocrine-resistance
#1
Jennifer M Giltnane, Katherine E Hutchinson, Thomas P Stricker, Luigi Formisano, Christian D Young, Monica V Estrada, Mellissa J Nixon, Liping Du, Violeta Sanchez, Paula Gonzalez Ericsson, Maria G Kuba, Melinda E Sanders, Xinmeng J Mu, Eliezer M Van Allen, Nikhil Wagle, Ingrid A Mayer, Vandana Abramson, Henry Gόmez, Monica Rizzo, Weiyi Toy, Sarat Chandarlapaty, Erica L Mayer, Jason Christiansen, Danielle Murphy, Kerry Fitzgerald, Kai Wang, Jeffrey S Ross, Vincent A Miller, Phillip J Stephens, Roman Yelensky, Levi Garraway, Yu Shyr, Ingrid Meszoely, Justin M Balko, Carlos L Arteaga
Inhibition of proliferation in estrogen receptor-positive (ER(+)) breast cancers after short-term antiestrogen therapy correlates with long-term patient outcome. We profiled 155 ER(+)/human epidermal growth factor receptor 2-negative (HER2(-)) early breast cancers from 143 patients treated with the aromatase inhibitor letrozole for 10 to 21 days before surgery. Twenty-one percent of tumors remained highly proliferative, suggesting that these tumors harbor alterations associated with intrinsic endocrine therapy resistance...
August 9, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28791499/long-term-peripheral-neuropathy-symptoms-in-breast-cancer-survivors
#2
Moaath Mustafa Ali, Machelle Moeller, Lisa Rybicki, Halle C F Moore
PURPOSE: Peripheral neuropathy (PN) is a common and distressing complication from chemotherapy. Symptoms often, but not always, improve with time. The prevalence of long-term PN symptoms in breast cancer survivors is not well known. We sought to explore PN symptoms and associated risk factors among breast cancer survivors at least 2 years out from diagnosis. METHODS: We performed a cross-sectional retrospective study investigating the prevalence of patient-reported numbness, tingling, and anesthesia symptoms as a surrogate for PN in breast cancer survivors...
August 8, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28776282/trends-in-adjuvant-therapies-after-breast-conserving-surgery-for-hormone-receptor-positive-ductal-carcinoma-in-situ-findings-from-the-national-cancer-database-2004-2013
#3
Yasuaki Sagara, Rachel A Freedman, Stephanie M Wong, Fatih Aydogan, Anvy Nguyen, William T Barry, Mehra Golshan
PURPOSE: Breast-conserving surgery (BCS) followed by radiotherapy (RT) with or without endocrine therapy (ET) is a standard treatment option for ductal carcinoma in situ (DCIS). We sought to investigate national patterns in the use of adjuvant therapy after BCS for hormone receptor (HR)-positive DCIS over time. PATIENTS AND METHODS: Using data from the National Cancer Data Base, we identified patients diagnosed with DCIS and treated with BCS between 2004 and 2013...
August 3, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28766208/contralateral-breast-cancer-risk-in-women-with-ductal-carcinoma-in-situ-is-it-high-enough-to-justify-bilateral-mastectomy
#4
Megan E Miller, Shirin Muhsen, Cristina Olcese, Sujata Patil, Monica Morrow, Kimberly J Van Zee
BACKGROUND: Women with ductal carcinoma in situ (DCIS) are increasingly choosing bilateral mastectomy. We sought to quantify rates of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) for DCIS, and to compare risk factors for CBC and IBTR. METHODS: From 1978 to 2011, DCIS patients undergoing BCS with a contralateral breast at risk were identified from a prospectively maintained database. The association of clinicopathologic and treatment factors with CBC and IBTR were evaluated using Kaplan-Meier analysis, multivariable Cox regression, and competing risk regression (CRR)...
August 1, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28760787/bridging-the-age-gap-in-breast-cancer-evaluation-of-decision-support-interventions-for-older-women-with-operable-breast-cancer-protocol-for-a-cluster-randomised-controlled-trial
#5
Karen Collins, Malcolm Reed, Kate Lifford, Maria Burton, Adrian Edwards, Alistair Ring, Katherine Brain, Helena Harder, Thompson Robinson, Kwok Leung Cheung, Jenna Morgan, Riccardo Audisio, Susan Ward, Paul Richards, Charlene Martin, Tim Chater, Kirsty Pemberton, Anthony Nettleship, Christopher Murray, Stephen Walters, Oscar Bortolami, Fiona Armitage, Robert Leonard, Jacqui Gath, Deirdre Revell, Tracy Green, Lynda Wyld
INTRODUCTION: While breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes among the older age group. It is inevitable that comorbidities/frailty rates are higher, which may increase the risks of some breast cancer treatments such as surgery and chemotherapy, many older women are healthy and may benefit from their use. Adjusting treatment regimens appropriately for age/comorbidity/frailty is variable and largely non-evidence based, specifically with regard to rates of surgery for operable oestrogen receptor-positive disease and rates of chemotherapy for high-risk disease...
July 31, 2017: BMJ Open
https://www.readbyqxmd.com/read/28751448/association-of-fgfr1-with-er%C3%AE-maintains-ligand-independent-er-transcription-and-mediates-resistance-to-estrogen-deprivation-in-er-breast-cancer
#6
Luigi Formisano, Kimberly Mae Stauffer, Christian D Young, Neil E Bhola, Angel L Guerrero-Zotano, Valerie M Jansen, Monica M Estrada, Katherine E Hutchinson, Jennifer M Giltnane, Luis J Schwarz, Yao Lu, Justin M Balko, Olivier Deas, Stefano Cairo, Jean-Gabriel Judde, Ingrid A Mayer, Melinda Sanders, Teresa C Dugger, Roberto Bianco, Thomas Stricker, Carlos L Arteaga
FGFR1 amplification occurs in ~15% of ER+ human breast cancers. We investigated mechanisms by which FGFR1 amplification confers antiestrogen resistance to ER+ breast cancer.<br /><br />Experimental Design: ER+ tumors from patients treated with letrozole before surgery were subjected to Ki67 immunohistochemistry, FGFR1 FISH, and RNA-sequencing. ER+/FGFR1 amplified breast cancer cells and patient-derived xenografts (PDXs) were treated with FGFR1 siRNA or the FGFR tyrosine kinase inhibitor lucitanib...
July 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28743374/a-systematic-review-of-generic-and-breast-cancer-specific-life-expectancy-models-in-the-elderly
#7
REVIEW
R Thomas, A Pieri, H Cain
INTRODUCTION: The use of primary endocrine therapy (PET) in managing breast cancer in the elderly has become common practice. Whilst there appears to be no difference in overall survival in comparison with surgery, PET has been found to be inferior in local disease control with a limited duration of efficacy (2-3 years). The International Society of Geriatric Oncology (SIOG) state that PET may be considered in patients with a short life expectancy (<2 years) or considered unfit for surgery...
July 18, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28730768/modulatory-effect-of-neoadjuvant-chemotherapy-on-the-prognosis-of-patients-with-breast-cancer
#8
Jasna Trifunovic, Numa Memisevic, Borislava Nikolin, Svetlana Salma, Tihomir Dugandzija, Vladimir Vidovic
PURPOSE: To evaluate the changes in biological markers ER, PR, HER2 and Ki67 in residual tumor after surgery for locally advanced breast cancer (LABC), and also to evaluate the outcome of breast cancer patients treated with neoadjuvant chemotherapy (NAC). METHODS: 144 breast cancer patients treated with NAC at the Oncology Institute of Vojvodina, Serbia from 2011 to 2015 were included in this study. Changes in biologic markers ER,PR, HER2/neu and Ki-67 were evaluated at diagnostic core biopsy and at the final surgery tissue specimens...
May 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28712671/analysis-of-stereotactic-biopsies-performed-on-suspicious-calcifications-identified-within-24-months-after-completion-of-breast-conserving-surgery-and-radiation-therapy-for-early-breast-cancer-can-biopsy-be-obviated
#9
Rosalind P Candelaria, Palita Hansakul, Alastair M Thompson, Huong Le-Petross, Vicente Valero, Roland Bassett, Monica L Huang, Lumarie Santiago, Beatriz E Adrada
BACKGROUND: To determine the cancer yield of stereotactic biopsy of suspicious calcifications identified within 24 months after breast conservation therapy (BCT). METHODS: Retrospective review of stereotactic biopsies performed during 2009-2013 for suspicious calcifications in the ipsilateral breast of patients who completed BCT. RESULTS: 94/2773 (3.4%) had stereotactic biopsies for suspicious calcifications in the ipsilateral breast; 7/94 (7...
July 1, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28702891/predictors-associated-with-mri-surveillance-screening-in-women-with-a-personal-history-of-unilateral-breast-cancer-but-without-a-genetic-predisposition-for-future-contralateral-breast-cancer
#10
John V Hegde, Xiaoyan Wang, Deanna J Attai, Maggie L DiNome, Amy Kusske, Anne C Hoyt, Sara A Hurvitz, Joanne B Weidhaas, Michael L Steinberg, Susan A McCloskey
PURPOSE: For women with a personal history of breast cancer (PHBC), no validated mechanisms exist to calculate future contralateral breast cancer (CBC) risk. The Manchester risk stratification guidelines were developed to evaluate CBC risk in women with a PHBC, primarily for surgical decision making. This tool may be informative for the use of MRI screening, as CBC risk is an assumed consideration for high-risk surveillance. METHODS: Three hundred twenty-two women with a PHBC were treated with unilateral surgery within our multidisciplinary breast clinic...
July 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28698832/acute-inflammatory-response-during-neoadjuvant-chemotherapy-for-locally-advanced-breast-cancer-a-case-report
#11
Xiaolan Feng, Tanya Berrang, John Paul McGhie, Peter Watson, R Petter Tonseth, Pauline T Truong
We report on a 56-year-old Caucasian female, diagnosed with locally advanced, hormone-receptor-positive, and human epidermal growth factor receptor 2 (HER2)-positive cancer of the left breast. The patient received neoadjuvant chemotherapy with adriamycin/cyclophosphamide (AC) followed by docetaxel/trastuzumab. A partial clinical and radiographical response was documented after four cycles of AC. Approximately one week after the first cycle of docetaxel and trastuzumab, the patient presented with diffuse edema, erythema, and induration involving the entire left breast...
June 10, 2017: Curēus
https://www.readbyqxmd.com/read/28697858/accelerated-partial-breast-irradiation-for-elderly-women-with-early-breast-cancer-a-compromise-between-whole-breast-irradiation-and-omission-of-radiotherapy
#12
Shakeel Sumodhee, Johan Levy, Emmanuel Chamorey, Daniel Lam Cham Kee, Marie-Eve Chand, Mathieu Gautier, Isabelle Peyrottes, Emmanuel Barranger, Jean-Michel Hannoun-Levi
PURPOSE: Regarding adjuvant radiation therapy making decision for elderly women, Albert (2013) published a nomogram predicting the mastectomy-free survival (MFS) rate with or without adjuvant irradiation. Based on this approach, we proposed to investigate the use of accelerated partial breast irradiation (APBI) vs. whole breast irradiation (WBI) or endocrine therapy alone in elderly low-risk breast cancer patients. METHODS AND MATERIALS: For each elderly woman treated by conserving surgery and APBI (multicatheter interstitial high-dose-rate brachytherapy), 5- and 10-year MFS rates were calculated...
July 8, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28696086/pregnancy-after-breast-cancer-hope-after-the-storm
#13
Valeria DE Simone, Olivia Pagani
INTRODUCTION: In the last decades, long-term outcomes of young women with breast cancer have greatly improved, raising several new survivorship needs which include fertility preservation and pregnancy. The prejudice against pregnancy after breast cancer is still alive among different healthcare providers (e.g. gynecologists, oncologists, general practitioners) and women are often confused and left alone in their family decision planning. EVIDENCE ACQUISITION AND SYNTHESIS: All the available retrospective data confirm pregnancy after breast cancer is safe both for the mother and the offspring, also in women with hormone receptor positive disease...
July 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28690652/prognostic-impact-of-progesterone-receptor-status-in-chinese-estrogen-receptor-positive-invasive-breast-cancer-patients
#14
Nan Yao, Zhenchuan Song, Xinle Wang, Shan Yang, Heng Song
PURPOSE: Estrogen receptor (ER) and progesterone receptor (PR) have been used as indicators of endocrine system status since the mid-1970s in the clinical management of breast cancer. The predictive role of ER in endocrine therapy is undisputed, but the prognostic value of PR is still debated. The aim of this study was to investigate the clinical characteristics and prognosis of ER positive breast cancer with different PR expression levels. METHODS: A population cohort of 3,030 primary invasive ER positive breast cancer patients from a single cancer center underwent surgery and received adjuvant endocrine therapy from 2004 to 2010...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28669712/lessons-in-precision-oncology-from-neoadjuvant-endocrine-therapy-trials-in-er-breast-cancer
#15
Matthew J Ellis
For post-menopausal women with clinical stage II/III estrogen receptor positive (ER+) breast cancer neoadjuvant endocrine therapy (NET) is an under-utilized and low-toxicity alternative to chemotherapy for increasing breast conservation rates. Individual responses to endocrine therapy can also be used to tailor systemic treatment. The Preoperative Endocrine Prognostic Index (PEPI) was developed to identify patients at low risk of relapse after NET so that adjuvant chemotherapy can safely be avoided. In a recent validation study, patients with pathological stage 1 or 2A breast cancers with a Ki67 value of 2...
June 30, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28654365/treatment-efficacy-adherence-and-quality-of-life-among-women-younger-than-35-years-in-the-international-breast-cancer-study-group-text-and-soft-adjuvant-endocrine-therapy-trials
#16
Poornima Saha, Meredith M Regan, Olivia Pagani, Prudence A Francis, Barbara A Walley, Karin Ribi, Jürg Bernhard, Weixiu Luo, Henry L Gómez, Harold J Burstein, Vani Parmar, Roberto Torres, Josephine Stewart, Meritxell Bellet, Antonia Perelló, Faysal Dane, Antonio Moreira, Daniel Vorobiof, Michelle Nottage, Karen N Price, Alan S Coates, Aron Goldhirsch, Richard D Gelber, Marco Colleoni, Gini F Fleming
Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled in the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). Methods In SOFT, women still premenopausal after surgery with or without chemotherapy were randomly assigned to tamoxifen alone, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. In TEXT, all received OFS with or without concomitant chemotherapy and were randomly assigned to exemestane plus OFS or tamoxifen plus OFS...
June 27, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28636294/-selective-therapeutic-de-escalation-in-early-stage-breast-cancer
#17
Aikaterini Liapi, Apostolos Sarivalasis, Wendy Jeanneret Sozzi, Loïc Lelièvre, Khalil Zaman
The survival of patients with breast cancer has improved considerably thanks to adjuvant radiotherapy and systemic treatments. Due to the potential adverse events associated with these treatments, a de-escalation effort was undertaken concerning surgery and more recently the adjuvant treatments. Conservative breast surgery and the avoidance of axillary dissection were possible for the majority of the patients without detrimental effect on survival. New radiotherapy techniques and the consideration of cancer biology allowed to better protect the peripheral organs and even to avoid treatment in certain low-risk patients...
May 17, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28592759/primary-breast-diffuse-large-b-cell-lymphoma-in-a-male
#18
Kiyonobu Tokuyama, Yasuaki Uemoto, Satoshi Kitagawa, Haruhiko Ohashi
A 74-year-old male with a mass in the right breast visited the Department of Breast and Endocrine Surgery in November 20XX. Core needle biopsy was performed. Pathological diagnosis was diffuse large B-cell lymphoma. The Ann Arbor clinical stage was IIA, and international prognostic index was low-intermediate. Six courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone and four courses of intrathecal chemotherapy were administered, and the patient achieved complete remission.
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28585885/validity-of-danish-breast-cancer-group-dbcg-registry-data-used-in-the-predictors-of-breast-cancer-recurrence-probecare-premenopausal-breast-cancer-cohort-study
#19
Deirdre P Cronin-Fenton, Anders Kjærsgaard, Thomas P Ahern, Marco Mele, Marianne Ewertz, Stephen Hamilton-Dutoit, Peer M Christiansen, Bent Ejlertsen, Henrik T Sørensen, Timothy L Lash, Rebecca A Silliman
BACKGROUND: Validation studies of the Danish Breast Cancer Group (DBCG) registry show good agreement with medical records for adjuvant treatment data, but inconsistent recurrence information. No studies have validated changes in menopausal status or endocrine therapy during follow-up. In a longitudinal study, we validated DBCG data using medical records as the gold standard. MATERIAL AND METHODS: From a cohort of 5959 premenopausal women diagnosed during 2002-2010 with stage I-III breast cancer, we selected 151 patients - 77 estrogen-receptor-positive and 74 estrogen-receptor-negative - from three hospitals...
June 6, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28585003/secondary-breast-carcinoma-after-completely-remitted-chronic-myeloid-leukemia-following-targeted-tyrosine-kinase-inhibitor-therapy
#20
Linlin Pan, Junwu Duan, Weiqiang Qiao, Lirong Bi, Di Wu, Zhimin Fan, Ming Yang
We describe a rare case of secondary breast carcinoma after chronic myeloid leukemia (CML) in a 56-year-old woman. The patient was treated with hydroxyurea and imatinib for CML and achieved complete remission (she has since been taking imatinib as the maintenance therapy). Four years later, the patient noticed a firm and painless lump in the left breast, which was diagnosed as ductal carcinoma in situ based on a percutaneous biopsy of the mass. Simple resection and sentinel lymph node biopsy of the left breast were then performed...
June 5, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
keyword
keyword
121072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"